Cancer Advisor

Edited and Updated: June 2026  Caution to the Reader: This is a complex, evolving topic rooted in molecular biology and evolutionary dynamics. The material below has been distilled for clinical accessibility while preserving strict mechanistic accuracy. Key conceptual frameworks from the Care Oncology Clinic (COC) protocol and Thomas Seyfried’s press–pulse model are integrated throughout. Introduction Clinicians utilizing a metabolic framework often combine 4–5 repurposed prescription agents with 4–5 nutraceuticals. While this approach frequently yields 1–2 years of sustained, stable response, acquired resistance can emerge rapidly, turning stable disease into aggressive progression. When this occurs, critical clinical questions arise: How should the regimen be modified? Should mechanistically similar agents be cycled more frequently? Should dosing be intermittent rather than continuous? What ...

Quick Answer: This framework merges OneDayMD's I-PREVENT Cancer Protocol with Dr. Paul Marik and Dr. Justus Hope's ROOT Protocol into a single five-layer system. Layer 1 is diet, metabolic health, and lifestyle — the original I-PREVENT foundation. Layers 2–3 are food-derived nutraceuticals (EGCG, curcumin, vitamin D3, omega-3, berberine, sulforaphane, vitamin C, magnesium, zinc, garlic, melatonin, and more), graded from strongest human-trial evidence to broader supporting data. Layer 4 is an optional Aged Garlic Extract upgrade. Layer 5 is Root 9 — the prescription drugs celecoxib, ivermectin, and mebendazole — which both authors scope strictly to people with confirmed hereditary cancer syndromes under specialist supervision, not general use. This is a prevention framework for healthy adults, not a cancer treatment protocol. Medically reviewed and updated by the OneDayMD Editorial Team | Merged framework published July 12, 2026 | Synthesizes and supersedes two ...

This is a supplementary article that contain the case details, sources and references for the primary compilation article . Note: The case reports below offer detailed, practical information on fenbendazole, ivermectin, and cancer that clinicians can find both useful and actionable. Fenbendazole and Ivermectin Prostate Cancer Case Series Compilation and Presentations This compilation features several case reports from multiple sources involving the use of ivermectin and/or fenbendazole for prostate cancer. Tables 1 - 3 below provide a summary of the information for the cases presented in this paper, including therapies used, dosage, outcome, and prior treatments. The cases are organised into tables grouped by primary drug emphasis (FBZ-focused (Table 1), IVM-focused (Table 2), or combinations (Table 3)). Each table includes key details: case number, patient demographics, cancer details, protocol, outcomes, and notes. Due to volume, only high-detail cases are prioritized. For details o...